Business Context and Reporting Period
This Form 8-K is filed by Tocagen Inc. (not Forte Biosciences, Inc.) on April 28, 2020. The report addresses a regulatory notice received from the Nasdaq Stock Market LLC regarding the Company's continued listing status.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, or debt. The sole financial metric referenced is the Company's stockholders' equity, which, as reported in the Form 10-Q for the quarter ended March 31, 2020, failed to meet the minimum requirement under Nasdaq Listing Rule 5450(b)(1).
Material Changes
- Delisting Notice: On April 28, 2020, the Company received formal notice from Nasdaq that its stockholders' equity is insufficient to satisfy continued listing standards.
- Compliance Timeline: The Company has 45 calendar days from the notice date to submit a plan to regain compliance.
Outlook, Risks, and Management Commentary
Management anticipates submitting a compliance plan to Nasdaq within the 45-day window. If accepted, the Company may receive an extension of up to 180 calendar days to demonstrate compliance. If the plan is rejected or compliance is not achieved, the Company may request a hearing before a Nasdaq Hearings Panel, which would stay any suspension or delisting action pending the hearing's conclusion.
Risks: The filing explicitly states there is no assurance the Company will regain compliance. Forward-looking statements regarding the plan submission and Nasdaq's response are subject to significant risks and uncertainties.
Investor Verification Checklist
- Verify the exact stockholders' equity figure reported in the Form 10-Q for the quarter ended March 31, 2020.
- Monitor the submission of the Company's compliance plan to Nasdaq within the 45-day deadline.
- Review the Company's capital raising activities or strategic actions intended to restore equity levels.
- Check for any subsequent filings regarding Nasdaq's acceptance or rejection of the compliance plan.